Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 107
- Registration Number
- NCT03599713
- Locations
- 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸Upmc Cancercenter, Pittsburgh, Pennsylvania, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 94
- Registration Number
- NCT03597295
- Locations
- 🇩🇰
Vejle Hospital, Vejle, Denmark
🇫🇷Centre Hospitalier Universitaire de Besancon, Besancon, France
🇺🇸Maryland Oncology Hematology P.A., Rockville, Maryland, United States
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT03589651
- Locations
- 🇺🇸
Rutgers Cancer Institute of Nj, New Brunswick, New Jersey, United States
🇺🇸Upmc Cancercenter, Pittsburgh, Pennsylvania, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 155
- Registration Number
- NCT03584516
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Jefferson University Hospitals, Philadelphia, Pennsylvania, United States
A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT03569371
- Locations
- 🇺🇸
Investigative Site, Hershey, Pennsylvania, United States
A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT03538041
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
🇮🇹AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARIT� DI NOVARA, Novara, Italy
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT03522142
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma
- First Posted Date
- 2018-05-02
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT03514407
- Locations
- 🇺🇸
UCLA Jonsson Comprehensive Cancer, Los Angeles, California, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇮🇹Istituto Ortopedico Rizzoli, Bologna, Italy
Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 14
- Registration Number
- NCT03497273
- Locations
- 🇯🇵
JA-Aichi Anjo Kosei Hospital, Anjo-Shi, Aichi, Japan
🇯🇵Hokkaido University Hospital, Sapporo-shi, Hokkaido, Japan
🇯🇵Kanagawa Cancer Center, Yokohama-shi, Kanagawa-Ken, Japan
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
- Conditions
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT03424122
- Locations
- 🇺🇸
Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University of Arizona Cancer Center - Out Pt., Tucson, Arizona, United States
🇺🇸Texas Oncology, Austin, Texas, United States